CVS Health Corp (CVS)

Likes diversified health care like this, including health insurance and pharmacy. They bought Oak Street for $9.5 billion and 10% of their market cap. Not profitable yet, but CVS will integrate Oak Street and raise profits. They just hired from Humana for Aetna a new and smart president. Sells at a good valuation and pays a 3.5% dividend. Weakness partially comes from not passing on higher costs to customers. He's held CVS for a while and has gone round-trip.

(Analysts’ price target is $107.13)

Its retail exposure is impacted with more prescriptions being filled online. He prefers UNH. 

Excellent entry point at current share price.
Recent M&A not supported by the market.
Believes long term prospects good for healthcare.
Looming recession not a concern.
Good long term investment. 
Vertically integrated healthcare company.

He owns a lot of health stocks. CVS has been a problem child all year, down 23%, but it's bottoming now. The market is figuring out their Oak Street buy and Signify and how that will be accretive.

It's starting to come back and is bottoming. The CEO is doing a great job and pays a 3.2% dividend yield and trades at 9x PE.

They do drug retail in the U.S. Also have a PBM business and health insurance. Their strategy is to broaden their offerings by buying companies. She owned this a few years ago. Trades at a low PE, but all those purchases and PBM is limited by outside forces to limit health costs, so this is an overhang.

He doesn't know why it is so low. The FMV is good and earnings look good as well. Hold if you have it and if the Book Value reaches his target of $60 to $65 buy more. Has great potential.

It's lagged 20% and is bottoming as they try to absorb Signify and Oak Street. Going forward, there is upside.

Shares have fallen due to rotation out of healthcare into energy & growth 
~3% yield attractive to investors.
Too defensive for investors at this stage in the cycle.
Value for long term investors.
Better options for investors who want capital gains. 

Disappointing. Two good acquisitions pending. Insurance division is losing market share. Covid gains downstream have waned. Growth lull, but almost a record low at 8x earnings. Huge addressable market. Will get mojo back.

Has pulled back a lot this year. Inexpensive and defensive.

Inexpensive. Frontline pharmacy, insurance, and PBM all rolled into one. Just bought a healthcare provider to tap into in-home and rural opportunities. Less than 10x earnings, big free cashflow. Market's nervous about debt, about $20B. CEO is a smart operator. Yield is 3.23%.

Very strong assets at large company.
Recent pullback in share price presenting good buying opportunity.
Significant upside possible for the long term.
Buy on weakness.

Management warned of headwinds, yet analysts have not changed estimates. FMV has been getting bigger as stock price has fallen. Nice balance sheet. Decent yield. Loads of upside, after potential short-term weakness to $75-76. Healthcare has been pummeled more than people were expecting. Be cautious buying more.

Similar but different. He owns JNJ, expects a resurgence of spending in the medical area. JNJ will also benefit from splitting up its businesses, and he expects increased value from this move.